8-K: Butterfly Network Announces Proposed Public Offering Amidst Preliminary Cash Position Update

Butterfly Network announces a proposed public offering of Class A common stock while estimating a cash balance of $92.8 million as of December 31, 2024, pending final audit.

Summary

• Butterfly Network, Inc. has announced the commencement of an underwritten public offering of Class A common stock.
• The company intends to grant underwriters a 30-day option to purchase up to an additional 15% of the shares sold in the offering.
• Butterfly Network plans to use the net proceeds from the offering to fund the development and commercialization of new and existing products and services, as well as for general corporate purposes.
• The offering is subject to market and other customary conditions, and there is no guarantee as to whether or when it will be completed or the actual size or terms.
• In connection with the offering, Butterfly Network estimates cash, cash equivalents, and restricted cash of approximately $92.8 million as of December 31, 2024.
• This cash estimate is preliminary and unaudited, and is subject to change upon completion of the company's financial statement closing procedures.
• The company's lease for its executive offices in Burlington, Massachusetts has been amended.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The company is raising capital, which could be seen as positive for growth but also indicates a need for funds. The preliminary cash position is a positive, but the unaudited nature introduces uncertainty.

Positives

• The public offering could provide Butterfly Network with significant capital to fund its growth initiatives.
• The company's existing cash position of approximately $92.8 million provides a financial foundation.
• The company's products have received industry recognition, including the iQ3 winning Best Medical Technology at the 2024 Prix Galien USA Awards.

Negatives

• The estimated cash balance of $92.8 million is preliminary and unaudited, and could change.
• The public offering is subject to market conditions, and there is no guarantee of its completion or terms.
• The company is undertaking a capital raise which may indicate a need for additional funding.

Risks

• Market conditions could impact the success and terms of the public offering.
• The preliminary cash estimate is subject to change upon completion of the financial close process.
• Failure to successfully develop and commercialize new products could impact future growth.
• The company acknowledges risks related to stock price volatility and uncertainties in financial markets, as detailed in their SEC filings.

Future Outlook

Butterfly Network intends to use the net proceeds from the offering to fund the development and commercialization of new and existing products and services, as well as for general corporate purposes.

Industry Context

The announcement reflects Butterfly Network's ongoing efforts to secure funding for its digital health and medical imaging technology, aligning with the broader trend of capital raising activities within the healthcare technology sector.

Comparison to Industry Standards

• Comparable companies in the medical device and digital health space, such as Teladoc Health and Dexcom, often utilize public offerings to fund research and development, sales and marketing, and general corporate expenses.
• The success of Butterfly Network's offering will likely be compared to recent offerings by similar companies in terms of pricing, investor demand, and subsequent stock performance.
• The company's focus on portable ultrasound technology positions it within a growing segment of the medical imaging market, where miniaturization and accessibility are key competitive factors.

Stakeholder Impact

• Shareholders will be impacted by the potential dilution from the public offering.
• Employees may benefit from increased investment in product development and commercialization.
• Customers could see improved and expanded product offerings.
• Suppliers and creditors may benefit from the company's strengthened financial position.

Next Steps

• File a preliminary prospectus supplement and accompanying prospectus with the SEC.
• Complete the underwritten public offering, subject to market and other conditions.
• Utilize the net proceeds from the offering for product development, commercialization, and general corporate purposes.
• Complete the fiscal year-end financial close process for the quarter ended December 31, 2024, and file the annual report on Form 10-K with the SEC.

Key Dates